Zinc Code UKRET012316 b Date of Prep November
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Role of pharmacists in patient education
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Pharmacists can reinforce the importance of adherence to treatment The effectiveness of TCS is often hampered by patients not adhering to their treatment 1 Poor adherence can lead to: Little improvement from topical therapy 1 x Temporary improvement and subsequent treatment failure 1 39% of patients with 24% of patients psoriasis (47/120) reported not adhering to their topical therapies; 2 fear of side effects is an important reason for non adherence 3 with AD (48/200) admitted to being non compliant due to fear of TCS side effects 4 Pharmacists’ advice and guidance can improve adherence to medication 5 1. Feldman SR, Yentzer BA. Am J Clin Dermatol. 2009; 10: 397– 06; 2. Richards HL, et al. J Am Acad Dermatol 1999; 41: 581– 583; 3. Brown KK, et al. J Am Acad Dermatol 2006; 55: 607– 613; 4. Charman CR, et al. Br J Dermatol 2000; 142: 931– 36; 5. Ryan R, et al. Cochrane Database Syst Rev 2014; Art No. CD 007768.
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Pharmacists can advise on the practical use of emollients General advice 1, 2 – – – Can be used as a soap substitute when bathing or washing Apply by smoothing into the skin along the line of hair growth (do not rub in!) Do not share with other people Consider keeping separate packs of emollients at work or school to facilitate frequent application Consider using better tolerated products (e. g. creams, lotions) during the day and ointments at night Emollients for AD 1 – Use liberally and frequently, even when skin appears improved or clear – Use during or after bathing – For very dry skin, applying every 2– 3 hours should be considered normal Emollients for psoriasis 2 – – Apply as often as required The amount of emollient used should far exceed the amount of TCS (by over 10: 1) Apply before anti psoriasistopical treatment Wait 30 minutes before applying any other treatments Practical tip for patients: If a skin reaction occurs, stop the product and use an alternative emollient or return to your prescriber All image licenses obtained from dreamstime. com 1. NICE. Eczema – atopic. Clinical Knowledge Summaries 2015; http: //cks. nice. org. uk/eczema atopic. Accessed September 2016; 2. NICE. Psoriasis. Clinical Knowledge Summaries 2014; http: //cks. nice. org. uk/psoriasis. Accessed September 2016.
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Pharmacists can provide practical advice on the use of TCS Be aware of the different FTUs required based on age and disease location 1 The patient’s doctor will commonly prescribe the lowest potency TCS capable of achieving the desired effect; 2 different potencies may be prescribed for different areas of the body or of disease severity, 1, 3 and patients may need support to use them appropriately Patients should follow their prescriber’s advice when using TCS (typically they are used 1– 2 times daily for a maximum of 4 weeks)4– 7 When TCS are used as directed, most side effects are rare and TCS are generally well tolerated 4– 7 TCS should be used alongside daily skin care routines 1 The patient should return to their doctor if treatment is unsuccessful, they encounter side effects, or they have any concerns regarding their treatment 1. NICE. Eczema – atopic. Clinical Knowledge Summaries 2015; http: //cks. nice. org. uk/eczema atopic. Accessed September 2016; 2. Eichenfield LF, et al. J Am Acad Dermatol 2014; 71(1): 116– 132; 3. NICE. Psoriasis. Clinical Knowledge Summaries 2014; http: //cks. nice. org. uk/psoriasis. Accessed September 2016; 4. Cutivate cream. Summary of Product Characteristics, February 2014; 5. Betnovate cream. Summary of Product Characteristics, Sept 2013; 6. Dermovate cream. UK Summary of Product Characteristics, Nov 2014; 7. Eumovate cream. Summary of Product Characteristics, March 2014.
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Role of the pharmacist in the rational use of TCS: Summary TCS are an important treatment option for AD and psoriasis but patients can be hesitant to use them, potentially leading to poor treatment adherence Appropriate use of TCS is central to maximising efficacy and minimising side effects Pharmacists can play a key role in educating patients about appropriate use, supporting them to get the most out of their treatment
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Prescribing information for Dermovate, Betnovate, Cutivate and Eumovate can be found below if you are viewing this webinar in adobe or can be found above if you are viewing this webinar in HCP. gsk. co. uk. Adverse events should be reported. Reporting forms and information can be found at ww. mhra. gov. uk/yellowcard. Adverse events should also be reported to Glaxo. Smith. Kline on 0800 221 441.
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Live Q&A (6 th December live broadcasts only) Please send through any questions to the speakers by using the Q&A box within the adobe meeting room. Thank you.
Zinc Code: UK/RET/0123/16 b Date of Prep: November 2016 Post 6 th December webinar broadcast If you have any further questions please send these through to GSK’s Customer Contact Centre: Email: customercontactuk@gsk. com Phone: +44 (0)800 221 441 For those who wish to review the webinar’s content again we will upload 4 short videos onto our healthcare professional website, which is a promotional website. The content will be made available as soon as possible via the link below: https: //hcp. gsk. co. uk/events. html Thank you.
- Slides: 8